Intravitreal Bevacizumab for Diabetic Macular Edema
只有注册用户可以翻译文章
登陆注册
链接已保存到剪贴板
状态
赞助商
Isfahan Ophthalmology Research Center
临床试验: NCT00703235
BioSeek: nct00703235
关键词
抽象
Diabetic macular edema is a common cause of visual loss among diabetic patients. Studies have demonstrated the role of vascular endothelial growth factor (VEGF) in the pathogenesis of edema.
This study designed to evaluate the effect of Intravitreal injection of a recombinant monoclonal anti-VEGF antibody, Bevacizumab, for treatment of diabetic macular edema.
日期
| 最后验证: | 05/31/2008 |
| 首次提交: | 06/19/2008 |
| 提交的预估入学人数: | 06/19/2008 |
| 首次发布: | 06/22/2008 |
| 上次提交的更新: | 06/19/2008 |
| 最近更新发布: | 06/22/2008 |
状况或疾病
Macular Edema
Diabetic Retinopathy
干预/治疗
Drug: Bevacizumab
相
相 2/相 3
资格标准
| 有资格学习的性别 | All |
| 接受健康志愿者 | 是 |
| 标准 | Inclusion Criteria: - Diabetes mellitus - Clinically significant macular edema - Possibility of performing macular OCT - Consent of patient for inclusion in the study Exclusion Criteria: - History of macular photocoagulation in less than 6 months of inclusion in the study - Necessity of surgical intervention - Rejection of the remaining in the study by patient |
